This site is intended for healthcare professionals
Drug news

NN 9535 (semaglutide) meets endpoints for type 2 diabetes in phase III trial- Novo Nordisk

Read time: 1 mins
Last updated:12th Jul 2015
Published:12th Jul 2015
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest